Compare CZWI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | TARA |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 236.1M |
| IPO Year | 2006 | 2014 |
| Metric | CZWI | TARA |
|---|---|---|
| Price | $21.04 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 48.3K | ★ 409.6K |
| Earning Date | 04-27-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | 8.96 | ★ 38.25 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.61 | $2.97 |
| 52 Week High | $24.43 | $7.82 |
| Indicator | CZWI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 51.63 |
| Support Level | $20.21 | $3.72 |
| Resistance Level | $22.62 | $4.23 |
| Average True Range (ATR) | 0.89 | 0.15 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 33.45 | 76.70 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.